ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR

Post time 2024-4-21 19:50:27

journal：Hypertension

Authors：Ao Liu; Huilin Xie; Fangyan Tian; Peiyuan Bai; Haobo Weng; Yu Liu; Wen Liu; Lu Tang; Hongmin You; Nianwei Zhou; Xianhong Shu

Published date：2023-12-

DOI：10.1161/hypertensionaha.123.21427

PDF link：https://www.ahajournals.org/doi/ ... ENSIONAHA.123.21427

Article link：http://dx.doi.org/10.1161/hypertensionaha.123.21427

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 2024-4-21 19:50:28

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AHA] ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AHA] ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AHA] ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR